哈药股份：10月24日召开董事会会议

Group 1 - The company announced that its 10th Board of Directors' 20th meeting was held on October 24, 2025, via telecommunication to review the Q3 2025 report and other documents [1] - The Chinese innovative drug sector has sold overseas authorizations worth $80 billion this year, indicating a strong performance in the biopharmaceutical secondary market [1] - Despite the robust activity in the secondary market, the primary market is facing challenges in fundraising, as noted by a partner from a prominent investment firm [1]